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 Abstract 
 
Purpose: To evaluate the performance of apparent diffusion coefficient (ADC) and 
lesion volume in potentially risk stratifying patients with prostate cancer (PCa). 
 
Materials and Methods: Men with elevated prostate specific antigen or abnormal digital 
rectal exam underwent a 3T multiparametric magnetic resonance imaging (mpMRI) with 
endorectal coil. ADC maps were calculated using b values of 0, 500, 1000 and 1500; 
additional images were obtained with b value of 2000. We prospectively enrolled 312 
men with lesions suspicious for cancer (suspicion score 2 - 5) on mpMRI. 
MRI/Ultrasound fusion-guided prostate biopsies were performed. Mean ADC of 
suspicious lesions were correlated against lesion volume, Gleason and D’Amico risk. 
 
Results: The cancer detection rate of fusion biopsy was 45.6% (206/452). Cancerous 
lesions were larger (median volume: 0.40 vs. 0.30 cm3; p=0.016). The median ADC (x 
10-6 mm2/sec) for lesions negative and positive for PCa were 984.5 and 666.5, 
respectively (p <0.0001). The AUC of ADC in predicting PCa was 0.79. Larger lesions 
were associated with higher risk PCa (Gleason and D’Amico) and lower ADC (all p 
<0.0001). 
 
Conclusions: The mean ADC of suspicious lesions on mpMRI was inversely correlated 
while lesion volume had a direct correlation with PCa detection. Future follow up studies 
are needed to assess longitudinal cancer risks of suspicious mpMRI lesions.  
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INTRODUCTION 
The incidence of prostate cancer (PCa) in the United States was estimated at 220,800 
cases in 2015 (1). Gleason score, D’Amico’s and Epstein’s criteria are grading systems 
currently used to risk stratify men with newly diagnosed clinically localized PCa, and 
thus help determine those who may quality for active surveillance rather than definitive 
treatment (2-4). About 50% of men who elect active surveillance will eventually require 
treatment, especially younger men, those with higher clinical stage, higher Gleason 
score, and higher prostate-specific antigen at diagnosis (5, 6). Furthermore, up to 20% 
of those diagnosed with clinically-localized low risk PCa may in fact harbor Gleason ≥7 
disease at the time of diagnosis (6). Hence, accurate risk stratification at the time of 
diagnosis is crucial to avoid over-treatment or potential delays in treatment.  
 
Previous reports, using various definitions such as Gleason’s score, D’Amico and 
Epstein’s criteria, have demonstrated an improved performance of multiparametric 
(mpMRI) in predicting clinically significant PCa, compared to traditional diagnostic tests 
such as prostate specific antigen (PSA) (7-12). Increased utilization of mpMRI has led to 
the next logical clinical question: can one stratify patients into different PCa risk 
categories using mpMRI sequence-specific quantitative data? The apparent diffusion 
coefficient (ADC) values calculated from diffusion weighted imaging (DWI), has been 
shown to correlate with PCa aggressiveness (13, 14). In an initial report, Turkbey et al 
reported a significant “negative” (inverse) correlation between calculated ADC values of 
tumors and their Gleason risk or D’Amico risk scores (13). However, only a relatively 
small sample of patients was evaluated and no comparisons were made with men 
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without PCa on biopsy (10). Herein, with a much larger cohort of patients, we report on 
the performance of apparent diffusion coefficient (ADC) and lesion volume in potentially 
risk stratifying patients with PCa. 
 
MATERIALS AND METHODS 
A retrospective analysis was performed in a cohort of men prospectively enrolled in an 
institutional review board (IRB)-approved phase III trial "MRI/TRUS Fusion-Guided 
Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer" (NCT 
01566045) at ##### School of Medicine. The details of this trial have been published in 
previous reports from our institution (8, 15, 16). Briefly, men with clinical suspicion for 
PCa [elevated (> 4ng/mL) or rising PSA or abnormal digital rectal exam (DRE)] between 
June 2012 and October 2014 were referred for mpMRI(2). Multiparametric MRI of the 
prostate was performed using a 3-Tesla Verio MRI machine (Siemens, Germany®), with 
a 16-channel cardiac coil (Sense, Invivo®) placed on the anterior pelvis, and an 
endorectal coil (ERC) (BPX-30, Medrad, Pittsburg, Penn®) filled with FC-770 (3M, St. 
Paul, MN®). MRI sequences obtained were:  a tri-planar T2-weighted (T2W) imaging; 
diffusion-weighted imaging (b-values 0, 50, 500, 1000, 1500, 2000) with apparent 
diffusion coefficient (ADC) mapping (b-values 0, 50, 500, 1000, 1500); and dynamic 
contrast-enhanced (DCE) MRI sequences using the European Society of Urogenital 
Radiology (ESUR) guidelines (17). The MRI studies were reviewed and interpreted by 
three genitourinary radiologists (##, ##, and ##), with more than 15 years combined 
experience, in a consensus. Lesions on mpMRI were graded on a 5-point Likert scale 
based on their suspicion for cancer, as described in the ESUR guidelines (17). Lesion 
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dimensions were measured individually based on 3D-region of interest segmentation on 
mpMRI and lesion volumes were estimated using the ellipsoid formula. ADC of each 
lesion was calculated as the mean ADC values measured in the whole lesion. The 
anatomic location of the lesions was reported using the NIH prostate zones, as 
previously reported (8). Men with suspicious lesion on mpMRI of the prostate were 
consented and enrolled into the trial.  
 
Demographic and clinical data were prospectively collected. The study protocol biopsies 
included fusion biopsy and a standard 12-core transrectal ultrasound (TRUS)-guided 
biopsy. The UroNav MRI/TRUS (end-fire iU22 ultrasound, Philips Healthcare, 
Netherlands) fusion guided-prostate biopsy system (Invivo, Florida®) was used to 
perform targeted biopsy of suspicious prostate lesion. A total of two biopsy cores (one 
each in the axial and sagittal planes) were obtained from each lesion, an approach 
shown to improve cancer detection by about 8% (18). A standard 12-core biopsy was 
then performed using TRUS guidance, with the UroNav workstation (Invivo, Gainesville, 
Florida®) turned off to blind the investigator to the anatomic location of the lesion. At our 
institution, a genitourinary pathologist (##) reviewed all biopsy specimens.  
 
These analyses were limited to men undergoing an initial or repeat biopsy with a 
suspicious lesion on mpMRI, no prior history of PCa, radiation to the pelvis, or inability 
to tolerate prostate biopsy under local anesthesia or mild sedation (Figure 1). 
 
Statistical Analysis 
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We compared demographic and clinical variables using Fisher’s exact tests and 
Kruskal-Wallis test for categorical and continuous variables respectively, between men 
diagnosed with cancer and those without cancer on protocol biopsies. We calculated 
and compared the cancer detection rate (CDR) of fusion, 12-core and protocol biopsies. 
On fusion biopsy, clinically significant PCa was defined as any Gleason ≥ 7 or Gleason 
6 with a lesion volume > 0.2 cm3 based on Epstein criteria which was developed using 
whole mount prostatectomy specimens. The performance of mpMRI in predicting PCa 
was evaluated using logistic regression and by plotting Receiver Operating 
Characteristic (ROC) curves, estimating AUCs and corresponding confidence intervals. 
Decision point analysis was performed to determine optimal cut off values for ADC; 
sensitivity and specificity were reported for each cut off point. Statistical level of 
significance was set at 0.05, and 2-sided p-values were reported.  
 
RESULTS 
A total of 312 men with suspicious lesion on mpMRI were eligible for analysis (Figure 1), 
of which 64.7% were diagnosed with PCa. The average number of suspicious mpMRI 
lesions was 1.45 (452/312); and PCa was detected on fusion biopsy in 45.6% (206/452) 
of lesions. Demographic, clinical, and radiological characteristics of men with cancer 
compared with men without cancer are presented in Table 1. In summary, men with 
PCa were more likely to be older, have an abnormal DRE, elevated PSA and PSA 
density, smaller prostate volume, larger lesion volume, and lower ADC value.  
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As presented in Table 2, the CDRs of 12-core biopsy, fusion biopsy, and protocol 
biopsies (12-core + fusion) were significantly associated with level of suspicion on 
mpMRI (p<0.0001), with 100% of those with suspicion level of 5 on mpMRI diagnosed 
with PCa and 98.0% with clinically significant PCa. The location of the lesion – 
peripheral zone or central gland – did not affect the performance of Fusion biopsy in 
detecting all PCa and clinically significant PCa (p<0.0001; Table 3).  
 
The median ADC value of mpMRI lesions in men with cancer was 666.5 x 10-6 
compared with 984.5 x 10-6 mm2/sec in men without cancer (Table 1; p<0.001). The 
AUC of ADC value in predicting PCa on fusion biopsy was 0.79 (95% CI: 0.75, 0.83) at 
the lesion level (Figure 2a). The optimal ADC cut off for predicting PCa was 719 x 10-6 
mm2/sec, characterized by a sensitivity and specificity of 63.6% and 82.5% respectively 
(Figure 2b). In a subgroup analysis, the AUC of ADC for predicting cancer in lesions 
located in the central gland was 0.83 (95% CI: 0.76, 0.90), which was not significantly 
different from 0.81 (95% CI: 0.76, 0.86) for lesions located in the peripheral zone of the 
prostate. However, the optimal ADC cut off for predicting PCa located in the central 
gland was 602 x 10-6 mm2/sec (range= 286 – 1350 x 10-6 mm2/sec; sensitivity = 64.6%; 
specificity = 89.4%) compared with 901 x 10-6 mm2/sec (range: 207 – 1650 x 10-6 
mm2/sec; sensitivity = 75.2%; specificity =76.1%) for lesions located in the peripheral 
zone of the prostate. 
 
The mean ADC value of suspicious mpMRI lesions was inversely correlated with the 
probability of PCa detection on fusion biopsy as well as the Gleason and D’Amico risk 
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stratification (Figure 3). The mean (± SD) ADC value of men without PCa, men with low, 
intermediate, and high Gleason risk PCa were 976.6 (± 252.1), 833.3 (± 275.5), 685.1 
(± 196.6), and 596.0 (± 153.9) x 10-6 mm2/sec respectively (p<0.0001; Figure 3a). 
Similarly, the mean (± SD) ADC value of men without PCa, men with low, intermediate, 
and high D’Amico risk PCa were 976.6 (± 252.1), 826.7 (± 277.2), 693.6 (± 206.6), and 
614.0 (± 156.7) x 10-6 mm2/sec respectively (p<0.0001; Figure 3b). 
 
The greater the volume of the suspicious lesion on mpMRI, the more likely it was to find 
a Gleason ≥7 PCa on fusion biopsy. For example, the detection rate of Gleason ≥7 PCa 
in lesions <0.20 cm3 was 24.3% compared with 47.6% for lesions ≥1.0 cm3 (p<0.001; 
Table 4). We observed an inverse correlation of ADC value with lesion volume on 
mpMRI, with larger lesions associated with lower ADCs. In an exploratory multivariable 
analysis combining ADC value and lesion volume in addition to age, family history, DRE 
findings, PSA, prostate volume to predict PCa, however, only ADC value was 
statistically significant (p <0.0001 vs. 0.3095).  
 
DISCUSSION 
The most commonly used risk stratification systems for prostate cancer include Gleason 
score, D’Amico’s criteria, Epstein’s criteria, and the National Comprehensive Cancer 
Network’s (NCCN’s) risk groups (2-4). Although several studies have reported on the 
ability of mpMRI of the prostate to enhance the detection of clinically significant PCa 
and improve risk stratification, incorporation of imaging findings in risk stratification is 
yet to be defined (7-9). Compared to mpMRI without ERC, the use of ERC has been 
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shown to increase the ability of mpMRI to detect more lesions including smaller lesions, 
with higher sensitivity and PPV. The use of ERC improves image quality by increasing 
signal-to-noise ratio and decreasing artifacts secondary to air in the rectum (19).  
 
ADC value was inversely correlated with PCa aggressiveness based on Gleason score 
or D’Amico’s criteria, as previously reported by several research groups (20-22). In an 
analysis of 48 patients who underwent MRI/TRUS-fusion guided prostate biopsies, 
Turkbey et al reported a “negative” (inverse) correlation between calculated ADC values 
of tumors and Gleason scores (13).  ADC value was found to accurately classify tumors 
into intermediate to high risk versus low risk in 73% of cases (13). In a much larger 
cohort of patients, we similarly report an inverse relationship between ADC and clinical 
significance of PCa. We found that the AUC of ADC in predicting PCa did not differ 
between th  central gland and peripheral zone of the prostate. The association between 
ADC and clinically significant PCa can be explained by the biology of PCa, 
characterized by impaired Brownian motion of water molecules due to hypercellularity, 
disorganized or complete loss of glandular architecture in higher-grade tumors, as 
previously hypothesized (13, 23, 24). Similar findings have been reported by other 
investigators who found that lower ADC values were strongly associated with higher 
tumor aggressiveness (22, 25).  
 
In defining the use of ADC value for PCa risk stratification, a cutoff point (s) needs to be 
defined. Kim et al (14) separated a cohort of patients with PCa into two groups using an 
ADC cut off of 830 x 10-6 mm2/sec, and reported that a higher ADC is predictive of 
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insignificant PCa (Gleason ≤ 6). However, the method of determination of this cutoff 
point was not reported. In our cohort, we determined that the optimal ADC cut off for 
defining cancerous versus benign lesions was 719 x 10-6 mm2/sec, with a sensitivity and 
specificity of 63.6% and 82.5% respectively. Furthermore, we found that the threshold 
ADC for PCa may differ between the central gland and peripheral zone - 602 x 10-6 
mm2/sec versus 901 x 10-6 mm2/sec respectively, which may reflect the varied cellularity 
of these zones of the prostate. Although analysis was limited to the peripheral zone 
only, Li et al reported a similar ADC threshold of 960 x 10-6 mm2/sec for differentiating 
cancerous versus benign lesions (26).  
 
Our analyses demonstrated other findings that may be useful in determining the clinical 
significance of PCa. We found an inverse correlation between mean ADC value of 
suspicious lesions and both the Gleason and D’Amico risk groups, with higher risk 
lesions characterized by lower mean ADC values, which may be attributed to the more 
restricted diffusion of molecules in cancerous versus benign tissue. We also found that 
the larger the lesion volume, the higher the risk or aggressiveness of the PCa. For 
example, 47.6% of lesions ≥ 1.0 cm3 were Gleason ≥7 tumors compared with 24.3% of 
lesions <0.2 cm3. In addition, we observed an inverse correlation between the ADC 
value of lesions and lesion volume, which again may be related to the hypercellularity of 
aggressive or larger tumors (23, 24). Although this association may be explained by the 
collinearity of ADC values and lesion volume, both mpMRI parameters (lesion volume 
and/or ADC value of suspicious lesion) may be useful in combination with clinical 
parameters to risk stratify men diagnosed with PCa.  
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Our study is not without limitations. First, for the purpose of these analyses, men with 
negative mpMRI were excluded since there was no lesion to target with fusion biopsy. 
However, mpMRI has been shown in multiple studies to select clinically significant PCa 
(8, 9, 15, 27, 28), with a high negative predictive value (>90%) (29). Second, a negative 
fusion biopsy may be due to assignment of a falsely high suspicion score or targeting 
error (30). In our study, a team of three radiologists interpreted the mpMRI images in a 
consensus format. As a result, we do not have data on inter-observer variability, which 
may characterize routine clinical practice. Although current recommendations support 
the use of consensus reads when starting an imaging program, we continued our 
consensus reads as part of our normal workflow. Radiology-pathology correlation and 
imaging quality review allowed for ongoing improvements and collaborations between 
all departm nts (31). In addition, two biopsy cores (one each in the axial and sagittal 
planes) were obtained from each lesion, an approach shown to improve cancer 
detection by about 8% (18). Third, we do not have radical prostatectomy specimens to 
determine the true positivity rate of suspicious lesions on mpMRI, hence theoretically 
some lesions may have been misclassified. Lastly, lesion volumes were estimated using 
the ellipsoid formula. This approach, however, may overestimate the actual volume by 
7% when compared to whole mount histopathology without a shrinkage factor correction 
(32). Nevertheless, the strength of this study lies in the prospective nature and 
comparatively larger sample size. In addition, the use of 3-Tesla MRI magnet and 
endorectal coil may have improved image quality and signal-to-noise ratio, and as a 
result, the performance of ADC value in stratifying PCa. Research is currently ongoing 
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to evaluate the utility of mpMRI and ADCs as a quantitative predictive parameter in the 
management of men with PCa on active surveillance.  
  
In conclusion, the calculated mean ADC value of suspicious lesions on mpMRI has an 
inverse relationship with lesion volume and prostate cancer risk or aggressiveness. Our 
study validates the findings of other groups, showing that ADC may be a useful tool in 
predicting PCa and its clinical significance. Furthermore, we report that lesion volume 
may be a useful tool to determine the clinical significance of prostate cancer. ADC 
values, lesion volume and its growth rate needs to be evaluated prospectively as 
parameters for monitoring eligible patients who elects active surveillance of their newly 
diagnosed low risk clinically localized PCa and/or in making a decision to proceed to 
treatment.  
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Tables 
 
Table 1. Demographic, Clinical, Radiological Characteristics of Men with and without 
Prostate Cancer (n = 312) 
Variable Cancer 
(n = 202) 
No Cancer 
(n = 110) 
p -
Value 
Age 66.0 [60.8 – 71.7] 63.9 [58.6 – 68.0] 0.142 
African American 30 (14.9) 10 (9.1) 0.160 
Family History of PCa 63 (31.2) 32 (29.1) 0.797 
Abnormal DRE 35 (17.3) 7 (6.4) 0.009 
PSA (ng/ml) 7.77 [5.5 – 12.5] 6.25 [4.6 – 8.9] 0.004 
PSAD (ng/ml/cm3) 0.18 [0.13 – 0.30] 0.10 [0.08 – 0.17] <0.001 
MRI Prostate Volume (cm3) 43.0 [30.0 – 58.0) 57.0 [40.7 – 70.3] <0.001 
MRI Lesion Volume (cm3) 0.37 [0.14 – 0.96] 0.25 [0.13 – 0.55] 0.016 
ADC of Lesion (x10-6 x mm2/sec) 666.5 [562.8 – 833.4] 984.5 [780.8 – 1160.2] <0.001 
Median [inter-quartile range] is reported for continuous variables and frequency (%) for 
categorical variables. Abbreviations: PCa: Prostate cancer; DRE: Digital rectal examination; 
PSA: Prostate specific antigen; PSAD: PSA density; MRI: Magnetic resonance imaging; ADC: 
Apparent diffusion coefficient. 
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Table 2. Cancer Detection Rates of Fusion and 12-Core for each level of suspicion on 
MRI (Patient level analysis; n = 312) 
Level of 
Suspicion 
N 
Cancer Detection Rate (%) 
12-Core only Fusion only Protocol Clin. Significant 
2 12 2 (16.7) 2 (16.7) 3 (25.0) 2 (16.7) 
3 135 53 (39.3) 36 (26.7) 60 (44.4) 38 (28.1) 
4 115 77 (67.0) 80 (69.6) 89 (77.4) 81 (70.4) 
5 50 36 (72.0) 48 (96.0) 50 (100.0) 49 (98.0) 
Total 312 168 (53.8) 166 (53.2) 202 (64.7) 170 (54.5) 
Abbreviations: MRI: Magnetic resonance imaging; Protocol = Fusion + 12-core 
biopsy. All p-values of comparison of MRI suspicion with CDR <0.0001 
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Table 3. Cancer Detection Rates of Fusion biopsy for each level of suspicion on MRI 
(Lesion level analysis; n = 452) 
Level of 
Suspicion 
Cancer Detection Rate (%) 
Peripheral Zone Central Gland 
N All PCa Clin Sig PCa N All PCa Clin Sig PCa 
2 23 2 (8.7) 1 (4.3) 1 0 (0) 0 (0.0) 
3 170 42 (24.7) 26 (15.3) 61 13 (21.3) 10 (16.4) 
4 102 72 (70.6) 65 (63.7) 43 26 (60.5) 26 (60.5) 
5 26 25 (96.2) 25 (96.2) 26 26(100.0) 26 (100.0) 
Total 321 144 (44.9) 117 (36.4) 131 65 (49.6) 62 (47.3) 
Abbreviations: MRI: Magnetic resonance imaging; PCa: Prostate cancer; All p-values of 
comparison of MRI suspicion with CDR <0.0001 
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Table 4. Correlation of Suspicious Lesion Volume on MRI with Gleason Risk 
Stratification on Fusion Biopsy (Lesion level analysis; n = 452) 
 
Histology 
Target Lesion Volume (cm3) 
Totals 
(n = 452) 
< 0.20 
(n =177) 
0.20 – 0.49 
(n = 126) 
0.50 – 0.99 
(n = 67) 
≥ 1.00 
(n = 82) 
No Cancer 107 (60.4) 69 (54.8) 38 (56.7) 32 (39.0) 246 (54.4) 
Gleason 
Risk 
6 27 (15.3) 12 (9.5) 5 (7.5) 11 (13.4) 55 (12.2) 
7 39 (22.0) 36 (28.6) 23 (34.3) 25 (30.5) 123 (27.2) 
8 – 10 4 (2.3) 9 (7.1) 1 (1.5) 14 (17.1) 28 (6.2) 
Abbreviations: MRI: Magnetic resonance imaging; p-value of comparison <0.0001 
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Figure Legends 
 
Figure 1. CONSORT Diagram of the "MRI/TRUS Fusion-Guided Prostate Biopsy - An 
Improved Way to Detect and Quantify Prostate Cancer" trial. Abbreviations: mpMRI – 
multiparametric magnetic resonance imaging; PCa – prostate cancer; and AS – active 
surveillanc . 
 
 
Figure 2. (a). Receiver Operating Characteristic Curve Depicting the Performance of 
ADC Value in predicting Prostate Cancer (AUC = 0.79; 95% CI: 0.75, 0.83); (b). 
Decision point analysis – Optimal ADC cut off = 719 x 10-6 mm2/sec (Sensitivity = 
63.6%, Specificity = 82.5%). Abbreviations: ADC – apparent diffusion coefficient; TPF – 
true positive fraction; and FPF – false positive fraction 
 
 
Figure 3. Correlation of ADC value of suspicious lesions with (a) Gleason risk 
stratification; and (b) D’Amico risk stratification (p<0.0001). Abbreviation: ADC – 
apparent diffusion 
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CONSORT Diagram of the "MRI/TRUS Fusion-Guided Prostate Biopsy - An Improved Way to Detect and 
Quantify Prostate Cancer" trial. Abbreviations: mpMRI – multiparametric magnetic resonance imaging; PCa 
– prostate cancer; and AS – active surveillance.  
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Figure 2. (a). Receiver Operating Characteristic Curve Depicting the Performance of ADC Value predicting 
Prostate Cancer (AUC = 0.79; 95% CI: 0.75, 0.83)  
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Figure 2. (b). Decision point analysis – Optimal ADC cut off = 719 x 10-6 mm2/sec (Sensitivity = 63.6%, 
Specificity = 82.5%)  
254x190mm (96 x 96 DPI)  
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Figure 3. Correlation of ADC value of suspicious lesions with (a) Gleason risk stratification  
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Figure 3. Correlation of ADC value of suspicious lesions with (b) D’Amico risk stratification (p<0.0001)  
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June 15
th
, 2016 
 
Mark E. Schweitzer, MD 
Editor-in-Chief, JMRI 
Stony Brook Department of Radiology 
HSC L4 Room 120 
Stony Brook, NY 11794-8460 
 
Dear Dr. Schweitzer, 
 
Thank you for the prompt review of our manuscript entitled " Risk Stratification of Prostate Cancer 
Utilizing Apparent Diffusion Coefficient Value and Lesion Volume on Multiparametric Magnetic 
Resonance Imaging." 
 
We appreciate your comments/recommendations and those of the reviewers, which we believe have 
strengthened our paper. Detailed below are point-by-point responses to the reviewer comments. Tracked 
changes were made to the manuscript to reflect these recommendations. A clean copy of the manuscript 
(with changes accepted) is also attached. 
 
Thanks for your consideration of this manuscript for publication in the Journal of Magnetic Resonance 
Imaging (JMRI). 
 
 
Yours sincerely, 
 
 
Sincerely, 
  
Ardeshir Rastinehad, D.O. 
 
 
General Response 
To clarify, we utilized the terms “risk” and “clinically significant” in the context of prostate cancer 
stratification. Prostate cancer is stratified into very low risk, low risk, intermediate risk, and high risk based 
on the probability of progression to metastatic disease or death.  
 
On the one hand, clinically significant prostate cancer comprises disease categories (intermediate and 
high risk groups) that should be treated, given the high probability of progression. Clinically insignificant or 
indolent disease (very low and low risk groups), on the other hand, refers to those prostate cancers that 
can be observed given the low probability of progression. Patients in this category tend to die with, not of 
prostate cancer. Please refer to the National Cancer Comprehensive Network (NCCN) prostate cancer 
guidelines (Reference #2) for further details. 
 
 
Reviewer: 1 
Comments to the Author 
This paper is good enough for reporting the evaluating the performance of ADC and lesion volumes in 
risk stratifying patients with prostate. 
Authors’ response: Thank you! 
 
I have some comments of this paper and I want you to modify this paper for understanding. 
*1. More detail explanation of Fig 1 is needed. 
Page 28 of 29
Journal of Magnetic Resonance Imaging
Journal of Magnetic Resonance Imaging
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
leFOR PEER REVIEW ONLY
Authors’ response: We have added an explanation of the abbreviations to the figure legend. Otherwise, 
the study flow diagram is self-explanatory. 
 
*2. You should explain about the Fig2(a). 
Authors’ response: We have added an explanation of the abbreviations to the figure legend; this figure 
was described and now referred to in the results.  
 
*3. You should explain the abbreviation, such as TRUS, MP-MRI, etc. 
Authors’ response: Thanks, these abbreviations have been explained. 
 
 
 
Reviewer: 2 
Comments to the Author 
Thank you for this nice paper. 
Authors’ response: Thank you! 
 
I have just small comments: 
You should discuss the limitations of fusion biopsy in the analyses of MRI lesions. Several data about a 
target error is published. 
Authors’ response: We have discussed this as one of the limitations. 
 
The authors should discuss the limitation when comparing different ADC values in different machines, 
with or without ERC. 
Authors’ response: Thanks for your comment. We believe that using a 3T MRI magnet and ERC may 
have improved the: 1) quality of MR images and thus the accuracy of interpretation; and 2) signal to noise 
ratio during image acquisition. We have included this in our discussion.  
 
 
 
Reviewer #3 
*1.     How many of these patients have been included in previous publications? 
Authors’ response: 140 patients with previous negative biopsies were included in a previous publication. 
We also used the same population in developing an MRI suspicion scoring system. However, the results 
presented in the current paper have NOT been reported previously. 
 
*2.     Figure 3 is compelling. What do the error bars represent? With no overlap across risk groups can 
risk be assigned by imaging and biopsy be avoided in some men? 
Authors’ response: These are box plots showing the minimum, interquartile range, and maximum ADC 
values in each risk category. Certainly with future validation studies, ADC value may be useful in risk 
stratifying men and biopsies may be avoided in those with low risk profile (i.e high ADC value) 
 
*3.     How was the ADC value determined in a lesion? Was it the lowest pixel value in the entire lesion? 
The mean value for the whole lesion? The mean value for a portion of the lesion? In men with multiple 
MRI lesions what was the ADC value that was used for analysis? 
Authors’ response: ADC was calculated as the mean ADC value in the whole lesion. We have ensured 
this is clearer in the manuscript. The analysis was performed at a lesion level (not patient level) i.e. every 
lesion was represented in the analysis. We analyzed 452 lesions from 312 patients.  
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